BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase

Molecular Pharmacology

Volumn 73, Issue 4, 2008, Pages 1244-1253

  Tiso, Mauro ^a,c   Strub, Andreas ^b,d   Hesslinger, Christian ^b   Kenney, Claire T ^a   Boer, Rainer ^b   Stuehr, Dennis J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Nycomed ^*  (Germany)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Nycomed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (4 METHOXY PYRIDIN 2 YL)ETHYL] 3H IMIDAZO[4,5 B]PYRIDINE; ARGININE; BYK 191023; CYTOCHROME P450; ENZYME INHIBITOR; HEME; INDUCIBLE NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CATALYSIS; CONTROLLED STUDY; EMBRYO; ENZYME INACTIVATION; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CELL; KINETICS; MACROPHAGE; PRIORITY JOURNAL;

ANAEROBIOSIS; ANIMALS; CARBON MONOXIDE; CELL LINE; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HEME; HUMANS; IMIDAZOLES; IRON; KINETICS; MICE; NADP; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; OXYGEN; PYRIDINES; TIME FACTORS; TRITIUM;

EID: 41149177030     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041319     Document Type: Article

References (38)

1. Abu-Soud HM, Loftus M, and Stuehr DJ (1995) Subunit dissociation and unfolding of macrophage NO synthase: relationship between enzyme structure, prosthetic group binding, and catalytic function. Biochemistry 34:11167-11175.
2. Adak S, Ghosh S, Abu-Soud HM, and Stuehr DJ (1999) Role of reductase domain cluster 1 acidic residues in neuronal nitric-oxide synthase. Characterization of the FMN-FREE enzyme. J Biol Chem 274:22313- 22320.
3. Alderton WK, Cooper CE, and Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357:593-615.
4. Baek KJ, Thiel BA, Lucas S, and Stuehr DJ (1993) Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem 268:21120-21129.
5. Blasko E, Glaser CB, Devlin JJ, Xia W, Feldman RI, Polokoff MA, Phillips GB, Whitlow M, Auld DS, McMillan K, et al. (2002) Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem 277:295-302.
6. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, and Tainer JA (1998) Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 279:2121-2126.
7. Demady DR, Jianmongkol S, Vuletich JL, Bender AT, and Osawa Y (2001) Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. Mol Pharmacol 59:24-29.
8. Gao YT, Panda SP, Roman LJ, Martasek P, Ishimura Y, and Masters BS (2007) Oxygen metabolism by neuronal nitric-oxide synthase. J Biol Chem 282:7921-7929.
9. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJ, and Knowles RG (1997) 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 272:4959-4963.
10. Hemmens B, Gorren AC, Schmidt K, Werner ER and Mayer B (1998) Haem insertion, dimerization and reactivation of haem-free rat neuronal nitric oxide synthase. Biochem J 332:337-342.
11. Hobbs AJ, Higgs A, and Moncada S (1999) Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 39:191-220.
12. Huang L, Abu-Soud HM, Hille R, and Stuehr DJ (1999) Nitric oxide-generated P420 nitric oxide synthase: characterization and roles for tetrahydrobiopterin and substrate in protecting against or reversing the P420 conversion. Biochemistry 38:1912-1920.
13. Lechner M, Lirk P, and Rieder J (2005) Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 15:277-289.
14. Lee AJ, Noon KR, Jianmongkol S, Lau M, Jenkins GJ, and Osawa Y (2005) Metabolism of aminoguanidine, diaminoguanidine, and NG-amino-L-arginine by neuronal NO-synthase and covalent alteration of the heme prosthetic group. Chem Res Toxicol 18:1927-1933.
15. Lehner MD, Marx D, Boer R, Strub A, Hesslinger C, Eltze M, Ulrich WR, Schwoebel F, Schermuly RT, and Barsig J (2006) In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitricoxide synthase. J Pharmacol Exp Ther 317:181-187.
16. Li H and Forstermann U (2000) Nitric oxide in the pathogenesis of vascular disease. J Pathol 190:244-254.
17. McMillan K and Masters BS (1993) Optical difference spectrophotometry as a probe of rat brain nitric oxide synthase heme-substrate interaction. Biochemistry 32:9875-9880.
18. Michel T and Feron O (1997) Nitric oxide synthases: which, where, how, and why? J Clin Invest 100:2146-2152.
19. Misra HP and Fridovich I (1972) The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem 247:6960-6962.
20. Moore DJ, West AB, Dawson VL, and Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28:57-87.
21. Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, and Morris SM Jr (2004) Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 170:148-153.
22. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, et al. (2008) Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111:402-410.
23. Nebbia C, Ceppa L, Dacasto M, and Carletti M (1999) Triphenyltin acetate-mediated in vitro inactivation of rat liver cytochrome P-450. J Toxicol Environ Health A 56:433-447.
24. Olken NM and Marletta MA (1993) NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 32:9677-9685.
25. Ortiz de Montellano PR, Nishida C, Rodriguez-Crespo I, and Gerber N (1998) Nitric oxide synthase structure and electron transfer. Drug Metab Dispos 26:1185-1189.
26. Paige JS and Jaffrey SR (2007) Pharmacologic manipulation of nitric oxide signaling: targeting NOS dimerization and protein-protein interactions. Curr Top Med Chem 7:97-114.
27. Panda K, Rosenfeld RJ, Ghosh S, Meade AL, Getzoff ED, and Stuehr DJ (2002) Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J Biol Chem 277:31020-31030.
28. Strub A, Ulrich WR, Hesslinger C, Eltze M, Fuchss T, Strassner J, Strand S, Lehner MD, and Boer R (2006) The novel imidazopyridine 2-[2-(4-methoxy- pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase. Mol Pharmacol 69:328-337.
29. Stuehr DJ (1996) Purification and properties of nitric oxide synthases. Methods Enzymol 268:324-333.
30. Stuehr DJ (1999) Mammalian nitric oxide synthases. Biochim Biophys Acta 1411: 217-230.
31. Tiso M, Konas DW, Panda K, Garcin ED, Sharma M, Getzoff ED, and Stuehr DJ (2005) C-terminal tail residue Arg1400 enables NADPH to regulate electron transfer in neuronal nitric-oxide synthase. J Biol Chem 280:39208-39219.
32. Wang J, Stuehr DJ, Ikeda-Saito M, and Rousseau DL (1993) Heme coordination and structure of the catalytic site in nitric oxide synthase. J Biol Chem 268:22255-22258.
33. Wei CC, Crane BR, and Stuehr DJ (2003) Tetrahydrobiopterin radical enzymology. Chem Rev 103:2365-2383.
34. White KA and Marletta MA (1992) Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31:6627-6631.
35. Xu W, Liu LZ, Loizidou M, Ahmed M, and Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311-320.
36. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, and Kuo L (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44:935-943.
37. Zhu Y, Nikolic D, Van Breemen RB, and Silverman RB (2005) Mechanism of inactivation of inducible nitric oxide synthase by amidines. Irreversible enzyme inactivation without inactivator modification. J Am Chem Soc 127:858-868.
38. Zimmermann N and Rothenberg ME (2006) The arginine-arginase balance in asthma and lung inflammation. Eur J Pharmacol 533:253-262.